A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051

NCT03301090 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

Corona Virus Infection

Interventions

OTHER: Placebo
BIOLOGICAL: REGN3048
BIOLOGICAL: REGN3051

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)